Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has provided an update.
AstraZeneca’s oncology portfolio gained momentum after a U.S. FDA advisory panel backed Truqap (capivasertib) combined with abiraterone and androgen deprivation therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer. The regimen would be the first targeted treatment for roughly one in four patients with this aggressive subtype, potentially strengthening AstraZeneca’s position in precision oncology if regulators follow the committee’s positive view.
The ODAC voted 7–1, with one abstention, that Phase III CAPItello-281 data show a favourable benefit-risk profile, including a 19% reduction in risk of radiographic progression or death and a 7.5‑month gain in median progression-free survival versus standard therapy. While overall survival data remain immature, interim results numerically favour Truqap, and parallel regulatory reviews in the EU underscore the global commercial and clinical stakes in expanding Truqap’s reach beyond its existing breast cancer indications.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong fundamentals (growth and profitability) and a constructive earnings outlook with pipeline and guidance support. It is held back by weak technical momentum and a valuation that looks elevated relative to the modest dividend yield, alongside near-term risks (notably Farxiga LOE and China pricing pressure).
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company with a major focus on oncology, developing targeted therapies and combination regimens for some of the most challenging cancers. The company has built a broad pipeline, including its AKT inhibitor Truqap, and aims to redefine cancer care by delivering life-changing medicines and improving long-term outcomes for patients worldwide.
Average Trading Volume: 2,668,518
Technical Sentiment Signal: Buy
Current Market Cap: £212.3B
Learn more about AZN stock on TipRanks’ Stock Analysis page.